Stabilized HIV Env Trimer Vaccine via Disulfide Bonds
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HIV vaccines face challenges in producing biochemically stable trimeric Env immunogens that elicit diverse neutralizing antibody responses, which is crucial for effective HIV vaccination outcomes.
Innovation Solution
Development of stabilized trimers composed of gp140 polypeptides with high amino acid sequence identity, including homotrimers and heterotrimers, to mimic the trimeric structure of HIV virions, which are used in vaccine compositions to induce broad immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional Env immunogens are used, then production is simpler, but biochemical stability is poor and they fail to elicit diverse neutralizing antibody responses
Solution Approach 1:
The gp160 Env protein is segmented into gp120 and gp41 subunits, with gp120 further divided into domains (V1-V5, CD4 binding site). This segmentation allows stabilization of the trimeric structure through controlled assembly of stabilized gp120 trimers with gp41, improving biochemical stability while enabling modular production approaches
Solution Approach 2:
The immunogen is constructed as a composite of multiple protein components: stabilized gp120 trimers (with engineered disulfide bonds and proline substitutions), gp41 subunits, and optional adjuvants. This composite structure achieves both biochemical stability and immunogenicity, resolving the contradiction between stability and manufacturability
2Adaptability or versatility
If highly variable Env protein is targeted, then neutralizing antibody responses are elicited, but vaccine effectiveness is reduced due to HIV diversity
Solution Approach 1:
The vaccine focuses on conserved regions of the Env protein (CD4 binding site, V1/V2, V3 loops) while maintaining the overall trimeric structure. By targeting specific local epitopes that are conserved across HIV clades A, B, and C, the vaccine achieves broad neutralizing capacity while maintaining reliability against diverse strains
Solution Approach 2:
The stabilized trimeric immunogen is designed to be universally effective against multiple HIV clades (A, B, C) by preserving conserved functional regions. The immunogen can elicit neutralizing antibodies that recognize multiple clades, achieving multi-functionality and broad protection while maintaining consistent structural properties
3Reliability
If trimeric structure is mimicked, then neutralizing antibody responses are enhanced, but production stability becomes difficult to achieve
Solution Approach 1:
Stabilizing modifications (disulfide bonds, proline substitutions) are introduced into the gp120 sequence before trimer assembly. This preliminary stabilization of individual subunits ensures that the trimeric structure remains stable during production and storage, while still maintaining the ability to elicit neutralizing antibody responses
Solution Approach 2:
The immunogen undergoes controlled parameter changes including disulfide bond formation, proline substitutions at specific positions, and glycosylation patterns. These parameter modifications stabilize the trimeric structure without compromising the immunogenicity and neutralizing capacity of the vaccine
Data Source
AI summary
The invention features stabilized human immunodeficiency virus (H IV) clade C envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and/or facilitate production of the stabilized HIV clade C Env trimers. In addition, the invention features methods of making and using the stabilized HIV clade C Env trimers of the invention.